SingleCognitive & Sleep

Cerebrolysin 60mg

Porcine-derived neuropeptide blend studied for neuroprotection, neuroplasticity, and central nervous system recovery pathways.

Mechanism

Acts by mimicking endogenous neurotrophic factors including BDNF, NGF, and GDNF to foster neuroprotection, synaptic plasticity, and neuronal repair mechanisms.

Dosing

Standard laboratory protocols initiate investigation at 20 mg daily, subsequently titrating up to 32 mg per day across divided administrations.

Reconstitution

Reconstituting a 60 mg vial with 3.0 mL of bacteriostatic water yields an active research solution of 20 mg/mL.

Storage

Store unmixed lyophilized vials frozen at -20°C shielded from light, and keep reconstituted liquid refrigerated at 2–8°C without refreezing.

Mix & measure Cerebrolysin 60mg

Pre-filled with this protocol's recommended BAC water and documented starting dose — edit any field to run your own numbers.

Mix & measure Cerebrolysin 60mg

Vial strength → BAC water → target dose

Vial strength

BAC water

Target dose

Concentration20.0mg/mL

Draw volume1.00mL

On the syringe100.0units

Total doses in vial: 3.0

100u80u60u40u20u0

U-100 syringe: 100 units = 1 mL

Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Advanced calculator →

Dosing Chart

Phase / Day(s)	Dose & Frequency	Volume (U-100 units / mL)
Week 1	20 mg (100 units), 1× daily	100 units (1.0 mL)
Week 2	24 mg/day, split 60u AM + 60u PM	120 units (1.2 mL)
Week 3	28 mg/day, split 70u AM + 70u PM	140 units (1.4 mL)
Week 4+	32 mg/day, split 80u AM + 80u PM	160 units (1.6 mL)

Reconstitution Steps

1
Draw 3.0 mL of bacteriostatic water into a clean, sterile syringe.
2
Gently inject the diluent along the glass interior wall of the vial to minimize foaming.
3
Carefully swirl and rotate the vial until the lyophilized contents are completely dissolved without shaking.
4
Mark the vial with preparation date and resulting concentration, then store immediately at 2–8°C away from light.

Supplies Needed

Peptide Vial

Lyophilized Cerebrolysin 60 mg research container

Insulin Syringes (U-100)

Sterile 1 mL syringes calibrated for precise micro-volume administration

Bacteriostatic Water

Sterile diluent containing 0.9% benzyl alcohol for peptide reconstitution

Alcohol Swabs

70% isopropyl alcohol wipes for vial septum and injection site disinfection

Why researchers study it

Cognition and nootropic pathway evaluation

Preclinical neuroprotection and survival signaling

Ischemic stroke and traumatic brain injury recovery

Dementia and neurodegenerative disease research

These describe what is being studied, not proven benefits, approved uses, or promised results.

Overview

Cerebrolysin is a complex biological preparation derived from enzymatic breakdown of porcine brain tissue. It comprises low-molecular-weight neuropeptides and free amino acids, designed to emulate the activity of endogenous neurotrophic proteins. While approved in dozens of countries internationally for conditions like stroke, vascular dementia, and traumatic brain injury, it remains unapproved by the FDA within the United States. In standard international medicine, Cerebrolysin is distributed as an aqueous concentrate for direct intravenous or intramuscular administration. However, within non-clinical investigative spaces, researchers often evaluate experimental lyophilized powder formulations using reconstituted subcutaneous protocols. These investigations center on deciphering how peptide fractions stimulate restorative cascades and protect cellular integrity under neurodegenerative stress. Scientific evaluations of Cerebrolysin yield varied outcomes across preclinical and clinical literature. While models of cellular stress frequently demonstrate notable anti-apoptotic and neurotrophic actions, larger human systematic reviews often document mixed or inconclusive results, driving continuous laboratory inquiry into its cellular mechanisms.

References

1.Journal of Neural Transmission, 2000 — Composition and neurotrophic hypothesis of Cerebrolysin
2.CNS & Neurological Disorders, 2007 — Pharmacological characterization and BDNF/NGF/GDNF-like actions
3.U.S. FDA, Drug Approvals — Regulatory status overview: not FDA-approved in the United States
4.EVER Neuro Pharma, Prescribing Information — International clinical approval status across 50+ countries
5.Stroke, 2005 — Preclinical neuroprotective and neurotrophic animal models
6.Frontiers in Neuroscience, 2019 — Experimental support for neuronal survival and plasticity
7.Cochrane Database of Systematic Reviews, 2022 — Insufficient evidence for Cerebrolysin in acute ischemic stroke